CellNovo

CellNovo

closed
Diabetes management system.

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2017201820192020
Revenues1.0m3.0m3.0m19.0m
% growth-200 %-533 %
EBITDA(17.0m)(12.0m)(13.0m)(10.0m)
% EBITDA margin(1700 %)(400 %)(433 %)(53 %)
Profit(17.0m)(14.0m)(14.0m)(12.0m)
% profit margin(1700 %)(467 %)(467 %)(63 %)
  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

Series A

£30.0m

Series B
N/A

€32.0m

Valuation: €100m

IPO
N/A

€5.4m

Post IPO Equity

€5.0m

Post IPO Equity
*

€17.5m

Post IPO Equity
Total Funding$39.6m

Recent News about CellNovo

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.